Clinical trials: Multiple Sclerosis, completed
Multiple Sclerosis
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
The study aimed to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation.
- Trial name
- MS-PEKOS (NCT06668324)
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Effect of a Mobile Health App on Pain and Quality of Life in Patients With Neuropathic Pain in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, leading to inflammation, neurodegeneration, and a range of physical and invisible symptoms.
- Trial name
- NCT06982742
- Testing
- Mobile Health App for Neuropathic Pain Management in MS
- Where
- Turkey (Türkiye)
- Volunteers
- 56 people
- Sponsor
- Meryem Kocaslan Toran
Multiple Sclerosis
Hand Grip Strength Correlates Strongly With Weekly Working Hours - the Importance of Upper Limb Function in Multiple Sclerosis
Multiple sclerosis (MS) as leading cause of non-traumatic neurological disability in young adults has additionally to the individual's burden of disease a significant influence on their ability to work.
- Trial name
- NCT07889271
- Testing
- hand grip strength
- Where
- Austria
- Volunteers
- 300 people
- Sponsor
- Salzburger Landeskliniken
Multiple Sclerosis, Spasticity, Muscle
Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity
This is a descriptive, prospective, non-controlled clinical investigation to be conducted on approximately 10 enrolled subjects at one site at Haukeland University Hospital in Bergen, Norway.
- Conditions
- Multiple Sclerosis, Spasticity, Muscle, Pain
- Trial name
- FlowOx-MS (NCT04904016)
- Testing
- FlowOx™
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Otivio AS
Multiple Sclerosis, Spasticity, Muscle
Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain
The study is a 4-week double-blind, randomized, controlled, parallel design investigation to investigate the impact of intermittent negative pressure on spasticity and pain in people with multiple sclerosis (pwMS).
- Conditions
- Multiple Sclerosis, Spasticity, Muscle, Pain, Chronic
- Trial name
- FO-NP002 (NCT05562453)
- Testing
- FlowOx 2.0
- Where
- Sweden
- Volunteers
- 56 people
- Sponsor
- Otivio AS
Multiple Sclerosis, Spasticity, Muscle
Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain
This study is based on a 4-week double-blind, randomized, controlled, parallel design investigation to investigate the impact of intermittent negative pressure on spasticity and pain in people with multiple sclerosis (pwMS)…
- Conditions
- Multiple Sclerosis, Spasticity, Muscle, Pain
- Trial name
- NCT05598736
- Testing
- FlowOx 2.0
- Where
- Norway
- Volunteers
- 58 people
- Sponsor
- Otivio AS
Multiple Sclerosis
Ai-Chi in Individuals With Multiple Sclerosis
The subject of this study is to examine the effects of Ai Chi-an aquatic exercise method-on balance, mobility, muscle strength, quality of life, depression, fatigue, and cognitive functions in individuals diagnosed with Multiple…
- Trial name
- Ai-Chi (NCT07880418)
- Testing
- Ai-Chi exercise, Land-Based Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Kirsehir Ahi Evran Universitesi
Multiple Sclerosis
Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility
Background: Research shows that both genes and the environment influence a person s risk for getting multiple sclerosis (MS). However, it is not possible to accurately predict who will develop MS.
- Trial name
- NCT01617395
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis
The need for improved diagnostic methods in Multiple Sclerosis (MS) is widely recognized. Although Magnetic Resonance Imaging (MRI) is a longstanding tool for detecting MS lesions, diagnostic inaccuracies persist.
- Trial name
- CAVS-MS (NCT04495556)
- Testing
- MRI
- Where
- 11 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- The Cleveland Clinic
Multiple Sclerosis
Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue
The overarching aim is to assess the role of microglial activation and norepinephrine transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission Tomography (PET) radiotracers, [F-18]PBR06 and…
- Trial name
- NCT04144257
- Testing
- [F-18]PBR06, [C-11]Methylreboxetine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital
Multiple Sclerosis
Evaluation of a Self-management Programme to Prevent Falls in People With Multiple Sclerosis
The goal of this randomized controlled trial is to evaluate the effects of a digital group based self-management fall prevention intervention, "Fewer Falls", in people with multiple sclerosis (PwMS).
- Trial name
- Fewer Falls (NCT05789225)
- Testing
- Fall prevention programme, Leaflet
- Where
- Sweden
- Volunteers
- 240 people
- Sponsor
- Karolinska Institutet
Multiple Sclerosis
In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging
Background: Contrast agents help things show up better on magnetic resonance imaging (MRI) scans. Researchers want to see if the drug ferumoxytol is a good contrast agent.
- Trial name
- NCT02511028
- Testing
- Ferumoxytol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis
Sleep disturbance is common in people with multiple sclerosis (MS) and contributes to diminished quality of life. Bright light therapy may be an innovative strategy to reduce sleep disturbance in MS, possibly through its effects…
- Trial name
- NCT04054050
- Testing
- Light therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Self Efficacy
Unidimensional Self-Efficacy Scale for Multiple Sclerosis (USE-MS) Turkish Adaptation
Multiple Sclerosis (MS) is a chronic, inflammatory, demyelinating, autoimmune disease of the central nervous system. Despite functional limitations and unpredictable disease course, individuals with MS are aimed to maintain…
- Trial name
- NCT06231030
- Testing
- Validity, Reliability and Adaptation
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 176 people
- Sponsor
- Nigde Omer Halisdemir University
Multiple Sclerosis, Urinary Incontinence
The Effect of Health Belief Model-Based Pelvic Floor Muscle Exercise Training on Urinary Incontinence and Quality of Life in Female Patients With Multiple Sclerosis
The aim of this study is to evaluate the effect of Pelvic Floor Muscle Exercise Training According to the Health Belief Model on Urinary Incontinence and Quality of Life in Female Patients with Multiple Sclerosis.
- Trial name
- NCT06805331
- Testing
- Intervention group(Pelvic Floor Muscle Exercise Training), control group
- Where
- Turkey (Türkiye)
- Volunteers
- 46 people
- Sponsor
- Nurgül KAPLAN
Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Cladribine Tablets as an Exit Therapy Strategy
The objective of the study is to evaluate the effectiveness of CladT, in terms of disease stability and safety, as the last treatment option in ageing MS patients vs treatment continuation and discontinuation This observational…
- Conditions
- Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- CLADREXIT (NCT06887426)
- Testing
- Cladribine
- Where
- France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis
Jacobson's Progressive Muscle Relaxation for Fatigue and Kinesiophobia in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic neurological condition that can cause fatigue and fear of movement (kinesiophobia), which may interfere with daily activities and participation in rehabilitation.
- Trial name
- JPMRT (NCT07854691)
- Testing
- Jacobson's Progressive Muscle Relaxation Technique (JPMRT), Routine Care
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Al-Zaytoonah University of Jordan
Multiple Sclerosis
Effectiveness of a One-year Group Program for Fatigue Management in Minimally Impaired People With Multiple Sclerosis
Fatigue is one of the most common symptoms, experienced by between 50% and 100% of people with multiple sclerosis (MS), and contributes significantly to the consequences of MS and perceived disability in the daily lives of those…
- Trial name
- HCB_MS (NCT07028879)
- Testing
- Fatigue management program
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Hospital Clinic of Barcelona
Multiple Sclerosis
Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis
The goal of this pilot study is to determine whether fecal microbial transplant (FMT) has the potential to be an effective, safe and tolerable therapy for the treatment of multiple sclerosis (MS).
- Trial name
- NCT04096443
- Testing
- Fecal microbial transplant (FMT)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Griffin Hospital
Multiple Sclerosis
Advancing Portable Brain Imaging: The NextMRI Project's Role in Revolutionizing Diagnostic MRI
Mobile imaging diagnostic devices are extremely valuable for clinical diagnosis both inside and outside healthcare facilities. However, Magnetic Resonance Imaging (MRI)-the gold standard for diagnosing many neurological and…
- Trial name
- NCT07037966
- Testing
- MRI
- Where
- Spain
- Volunteers
- 75 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe